Non-invasive evaluation of lung issues in asthma and cystic fibrosis using breath analysis
Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
This study is testing if analyzing breath samples can help find signs of lung problems and infections in people with asthma and cystic fibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Sex | All |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic Academic / other |
| Locations | 1 site (Olomouc) |
| Trial ID | NCT04157361 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze exhaled breath condensate (EBC) to identify biomarkers associated with pulmonary inflammation and infections in patients with bronchial asthma and cystic fibrosis. By establishing EBC 'breathprints', the researchers hope to correlate these molecular signatures with the severity of lung disease and the presence of specific bacterial infections, particularly from opportunistic pathogens like Pseudomonas aeruginosa. The study will include children and adults with asthma and cystic fibrosis, as well as healthy controls, to validate the effectiveness of EBC as a diagnostic tool. The ultimate goal is to enhance early detection and monitoring of lung conditions in these patients.
Who should consider this trial
Good fit: Ideal candidates include children and adults with moderate or IgE-mediated asthma, cystic fibrosis, or healthy individuals without lung disorders.
Not a fit: Patients with severe lung disorders not included in the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved non-invasive diagnostic methods for monitoring lung health in asthma and cystic fibrosis patients.
How similar studies have performed: Other studies have shown promise in using breath analysis for respiratory conditions, but this specific approach using EBC breathprints is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children/adults with moderate or IgE mediated asthma * Children/adults with cystic fibrosis * Healthy control children/adults without lung disorders Exclusion Criteria: \-
Where this trial is running
Olomouc
- University Hospital Olomouc — Olomouc, Czechia (Recruiting)
Study contacts
- Study coordinator: Petr Dzubak, MD, PhD.
- Email: petr.dzubak@upol.cz
- Phone: 585632150
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.